載入中
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
收盤時
US$3.68
−US$0.08 · -2.13%
盤後
US$3.68
US$0.00 · 0.00%
10月13日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
日內區間
目前US$3.68
52週區間
目前US$3.68
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
46
合理估值
情緒
56
多空交錯
風險
75
高風險
動能
18
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
日內區間
目前US$3.68
52週區間
目前US$3.68
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 29.91萬 USD | — | — | — | — |
| 毛利 | 29.91萬 USD | — | — | — | — |
| 研究與開發 | 32.22萬 USD | 159.87萬 USD | 197.49萬 USD | 632.49萬 USD | 433.64萬 USD |
| 銷售、一般及管理費用 | 902.4萬 USD | 521.2萬 USD | 633.89萬 USD | 981.01萬 USD | 828.19萬 USD |
| 營業費用 | 934.62萬 USD | 681.07萬 USD | 831.39萬 USD | 1613.5萬 USD | 1261.83萬 USD |
| 利息收入 | 44.29萬 USD | 127.59萬 USD | 164.9萬 USD | 33.5萬 USD | 7110 USD |
| 折舊和攤銷 | 3616 USD | 5580 USD | 6347 USD | 5714 USD | 4966 USD |
| 營業利益 | −904.72萬 USD | −681.07萬 USD | −831.39萬 USD | −1613.5萬 USD | −1261.83萬 USD |
| 淨利 | −2873.74萬 USD | −1276.85萬 USD | −603.85萬 USD | −557.4萬 USD | −1261.12萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Extended Market ETFVXF
Vanguard Morningstar Total Stock Market ETFVTI
iShares Micro-Cap ETFIWC
U.S. Micro Cap Portfolio ETFDFMCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
